BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 26239088)

  • 1. Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma.
    Kiyasu J; Miyoshi H; Hirata A; Arakawa F; Ichikawa A; Niino D; Sugita Y; Yufu Y; Choi I; Abe Y; Uike N; Nagafuji K; Okamura T; Akashi K; Takayanagi R; Shiratsuchi M; Ohshima K
    Blood; 2015 Nov; 126(19):2193-201. PubMed ID: 26239088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of programmed cell death 1/programmed cell death ligand 1 in the tumor microenvironments of primary gastrointestinal diffuse large B cell lymphomas.
    Liu Y; Ma J; Yu K; Li M; Liu F; Yan Q; Wang Z; Guo S
    Pathol Res Pract; 2018 Apr; 214(4):507-512. PubMed ID: 29598887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and clinical value of programmed cell death-ligand 1 (PD-L1) in diffuse large B cell lymphoma: a retrospective study.
    Hu LY; Xu XL; Rao HL; Chen J; Lai RC; Huang HQ; Jiang WQ; Lin TY; Xia ZJ; Cai QQ
    Chin J Cancer; 2017 Dec; 36(1):94. PubMed ID: 29246182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.
    Kwon D; Kim S; Kim PJ; Go H; Nam SJ; Paik JH; Kim YA; Kim TM; Heo DS; Kim CW; Jeon YK
    Histopathology; 2016 Jun; 68(7):1079-89. PubMed ID: 26426431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: Prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells.
    Ishikawa E; Kato S; Shimada K; Tanaka T; Suzuki Y; Satou A; Kohno K; Sakakibara A; Yamamura T; Nakamura M; Miyahara R; Goto H; Nakamura S; Hirooka Y
    Cancer Med; 2018 Dec; 7(12):6051-6063. PubMed ID: 30449068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
    Xie M; Huang X; Ye X; Qian W
    Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 expression is low in large B-cell lymphoma with MYC or double-hit translocation.
    Elbaek MV; Pedersen MØ; Breinholt MF; Reddy A; Love C; Clasen-Linde E; Knudsen H; Nielsen SL; Gang AO; Høgdall E; Dave S; Nørgaard P
    Hematol Oncol; 2019 Oct; 37(4):375-382. PubMed ID: 31408531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-1 expression on tumour-infiltrating cells is a prognostic factor for relapsed or refractory diffuse large B-cell lymphoma.
    Wada F; Kamijo K; Shimomura Y; Yamashita D; Hara S; Ishikawa T
    Immunology; 2024 Feb; 171(2):224-234. PubMed ID: 37904615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications.
    Xing W; Dresser K; Zhang R; Evens AM; Yu H; Woda BA; Chen BJ
    Oncotarget; 2016 Sep; 7(37):59976-59986. PubMed ID: 27527850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma.
    Fang X; Xiu B; Yang Z; Qiu W; Zhang L; Zhang S; Wu Y; Zhu X; Chen X; Xie S; Yi X; Liang A; Zeng Y
    Medicine (Baltimore); 2017 Apr; 96(15):e6398. PubMed ID: 28403071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD3+/CD8+ T-cell density and tumoral PD-L1 predict survival irrespective of rituximab treatment in Chinese diffuse large B-cell lymphoma patients.
    Shi Y; Deng L; Song Y; Lin D; Lai Y; Zhou L; Yang L; Li X
    Int J Hematol; 2018 Sep; 108(3):254-266. PubMed ID: 29748856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic implication of PD-L1 and phosphorylated STAT3 expression in diffuse large B cell lymphoma.
    Kwon HJ; Yang JM; Lee JO; Lee JS; Paik JH
    J Transl Med; 2018 Nov; 16(1):320. PubMed ID: 30458835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic implications of the tumor immune microenvironment and immune checkpoint pathway in primary central nervous system diffuse large B-cell lymphoma in the North Indian population.
    Parkhi M; Chatterjee D; Bal A; Vias P; Yadav BS; Prakash G; Gupta SK; Radotra BD
    APMIS; 2022 Feb; 130(2):82-94. PubMed ID: 34862664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells.
    Dong L; Lv H; Li W; Song Z; Li L; Zhou S; Qiu L; Qian Z; Liu X; Feng L; Meng B; Fu K; Wang X; Pan-Hammarström Q; Wang P; Wang X; Zhang H
    Oncotarget; 2016 May; 7(22):33350-62. PubMed ID: 27147575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
    Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
    Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed cell death-ligand 1 (PD-L1)
    Kimura S; Oshiro Y; Iwasaki H; Kadowaki M; Mihashi Y; Sakata T; Kawauchi S; Wang Z; Takamatsu Y; Takeshita M
    Clin Exp Med; 2022 Aug; 22(3):411-419. PubMed ID: 34515880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrative analysis of PD-L1 DNA status, mRNA status and protein status, and their clinicopathological correlation, in diffuse large B-cell lymphoma.
    Sun C; Jia Y; Wang W; Bi R; Wu L; Bai Q; Zhou X
    Histopathology; 2019 Mar; 74(4):618-628. PubMed ID: 30286249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic significance of programmed cell death protein 1 and its ligand on lymphoma cells and tumor-immune cells in diffuse large B-cell lymphoma, not otherwise specified.
    Slak TC; Miceska S; Gasljevic G; Boltezar L; Kloboves-Prevodnik V
    Radiol Oncol; 2024 Mar; 58(1):99-109. PubMed ID: 38378036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of PD-L1 detection assays and corresponding significance in evaluation of diffuse large B-cell lymphoma.
    Huang S; Nong L; Liang L; Zheng Y; Wang W; Liu J; Li D; Li X; Wang Y; Zhang B; Li T
    Cancer Med; 2019 Jul; 8(8):3831-3845. PubMed ID: 31150165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 expression on neoplastic or stromal cells is respectively a poor or good prognostic factor for adult T-cell leukemia/lymphoma.
    Miyoshi H; Kiyasu J; Kato T; Yoshida N; Shimono J; Yokoyama S; Taniguchi H; Sasaki Y; Kurita D; Kawamoto K; Kato K; Imaizumi Y; Seto M; Ohshima K
    Blood; 2016 Sep; 128(10):1374-81. PubMed ID: 27418641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.